Atria Investments’s Ascendis Pharma A/S ASND Stock Holding History

Atria Investments’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.43M	Buy	5,344 +1,350	+34%	+$315K	0.01%	923
2026 Q1	$914K	Buy	3,994 +257	+7%	+$57.6K	0.01%	1104
2025 Q4	$797K	Sell	3,737 -526	-12%	-$109K	0.01%	1185
2025 Q3	$848K	Sell	4,263 -153	-3%	-$28.5K	0.01%	1136
2025 Q2	$762K	Buy	4,416 +1,971	+81%	+$321K	0.01%	1188
2025 Q1	$381K	Buy	2,445 +9	+0.4%	+$1.29K	﹤0.01%	1491
2024 Q4	$335K	Buy	2,436 +393	+19%	+$51.7K	﹤0.01%	1542
2024 Q3	$305K	Buy	2,043 +6	+0.3%	+$810	﹤0.01%	1615
2024 Q2	$278K	Buy	+2,037	New	+$277K	﹤0.01%	1633
2022 Q2	–	Sell	-10,674	Closed	-$1.25M	–	756
2022 Q1	$1.25M	Buy	10,674 +1,098	+11%	+$127K	0.02%	751
2021 Q4	$1.29M	Buy	9,576 +88	+0.9%	+$13.1K	0.02%	732
2021 Q3	$1.51M	Sell	9,488 -671	-7%	-$91.8K	0.03%	639
2021 Q2	$1.34M	Buy	10,159 +947	+10%	+$126K	0.03%	659
2021 Q1	$1.19M	Buy	9,212 +2,371	+35%	+$360K	0.03%	646
2020 Q4	$1.14M	Buy	+6,841	New	+$1.13M	0.03%	628
2020 Q2	–	Sell	-3,497	Closed	-$394K	–	535
2020 Q1	$394K	Sell	3,497 -1,812	-34%	-$235K	0.03%	396
2019 Q4	$739K	Buy	+5,309	New	+$590K	0.02%	646
2019 Q3	–	Sell	-4,466	Closed	-$509K	–	858
2019 Q2	$509K	Buy	4,466 +417	+10%	+$49.9K	0.02%	574
2019 Q1	$477K	Sell	4,049 -673	-14%	-$58.9K	0.02%	544
2018 Q4	$296K	Sell	4,722 -117	-2%	-$7.35K	0.01%	656
2018 Q3	$343K	Sell	4,839 -128	-3%	-$8.81K	0.01%	719
2018 Q2	$330K	Buy	4,967 +1,731	+53%	+$114K	0.01%	712
2018 Q1	$212K	Buy	+3,236	New	+$182K	0.01%	795

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Atria Investments's ASND Position: Q2 2026 in Review

Atria Investments increased its Ascendis Pharma A/S (ASND) stake by 34% in Q2 2026, buying an estimated $315K and bringing the position to 5,344 shares worth $1.43M. The position accounts for 0.01% of the portfolio, ranked #923.

Atria Investments first reported a position in ASND in Q1 2018 and has held it in 23 quarters since. The position peaked at $1.51M in Q3 2021. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Atria Investments held 5,344 shares of Ascendis Pharma A/S worth $1.43M as of Q2 2026.
Atria Investments bought 1,350 Ascendis Pharma A/S shares in Q2 2026, an estimated $315K.
Ascendis Pharma A/S made up 0.01% of Atria Investments's portfolio in Q2 2026, its #923 holding.
Atria Investments first reported a position in Ascendis Pharma A/S in Q1 2018 and has held it in 23 quarters since.
Atria Investments's Ascendis Pharma A/S position peaked at $1.51M in Q3 2021.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Atria Investments's 13F filing for Q2 2026, filed 28 Jul 2026.